clinical trial · NCT05198557
A Study of MT-0551 in Patients With Systemic Sclerosis
Systemic SclerosisInebilizumabPlacebo
brief summary
The study will verify the superiority of MT-0551 to placebo at 26 weeks after treatment initiation in systemic sclerosis (SSc) patients using the modified Rodnan Total Skin thickness Score (mRTSS) as a measure of skin thickening. The safety and pharmacokinetics will also be investigated.
started
Jul 20, 2022
primary completion
Jul 31, 2025
completion
Aug 1, 2026
last updated
Dec 8, 2025
official title
Phase 3 Study of MT-0551 in Patients With Systemic Sclerosis (Placebo-Controlled Double-Blind Study)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol